Home
About Us
Team
Services
News
Partners
Advisory Board
Contact
News
Exacis Biotherapeutics Announces Key Additions to Company’s Scientific Advisory Board
Aardvark Therapeutics, Inc., Completes $29M Series B Funding Led by Sorrento Therapeutics and Including Existing Investors and The Foundation for Prader-Willi Research
Richard Gabriel, B.S., M.B.A., Life Sciences Entrepreneur, Joins CSG Advisory Board; Deirdre Y. Gillespie, M.D., Steps Down After 15 Years
Exacis Biotherapeutics Makes Strategic Investment in Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience
Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors
Back To Top
